Alkermes plc Q2 2025 Earnings Recap

Alkermes delivered strong financial results in Q2 2025, achieving robust revenue growth and successfully advancing its innovative treatment for narcolepsy, positioning the company for significant future growth.

Key Takeaways

• Q2 total revenues reached $390.7 million, with proprietary product sales growing 14% year-over-year to $307.2 million.
• Alixorexton's Phase II study, Vibrance 1, showed significant effects on wakefulness and cognitive improvements in narcolepsy patients, setting the stage for Phase III trials.
• The company boasts a solid financial position with $1 billion in cash, no debt, and expected Q3 net sales between $280 million to $300 million.